Silo Pharma (SILO) Stock Price, News & Analysis

Company Overview

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Key Stats

• Today's Range: $0.67 to $0.69
• 50-Day Range: $0.43 to $0.69
• 52-Week Range: $0.41 to $3.37
• Volume: 81,453 shs
• Average Volume: 1.85 million shs
• Market Capitalization: $3.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Silo Pharma Stock Analysis - MarketRank™

Silo Pharma scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Silo Pharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Silo Pharma is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Silo Pharma is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Silo Pharma has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.66% of the float of Silo Pharma has been sold short.

Short Interest Ratio / Days to Cover

Silo Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Silo Pharma has recently decreased by 56.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Silo Pharma does not currently pay a dividend.

Dividend Growth

Silo Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.66% of the float of Silo Pharma has been sold short.

Short Interest Ratio / Days to Cover

Silo Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Silo Pharma has recently decreased by 56.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 3 people have searched for SILO on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Silo Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,300.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 4.37% of the stock of Silo Pharma is held by insiders.

Percentage Held by Institutions

Only 5.58% of the stock of Silo Pharma is held by institutions.

SILO Stock Analysis - Frequently Asked Questions

How have SILO shares performed this year?

Silo Pharma's stock was trading at $0.89 at the beginning of the year. Since then, SILO stock has decreased by 23.9% and is now trading at $0.6770.

How were Silo Pharma's earnings last quarter?

Silo Pharma, Inc. (NASDAQ:SILO) released its earnings results on Friday, May, 9th. The company reported ($0.23) EPS for the quarter. The company had revenue of $0.02 million for the quarter. Silo Pharma had a negative net margin of 6,420.83% and a negative trailing twelve-month return on equity of 84.88%.

How do I buy shares of Silo Pharma?

Shares of SILO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Silo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Silo Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Citius Pharmaceuticals (CTXR), Sunshine Biopharma (SBFM), AbbVie (ABBV) and Biorestorative Therapies (BRTX).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 7/24/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Apparel
• Current Symbol: NASDAQ:SILO
• CIK: 1514183
• Web: silopharma.com
• Phone: (718) 400-9031
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.39 million
• Net Margins: -6,420.83%
• Pretax Margin: -6,419.44%
• Return on Equity: -84.88%
• Return on Assets: -61.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.73
• Quick Ratio: 4.73

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 44.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.12 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 4,480,000
• Free Float: 4,288,000
• Market Cap: $3.11 million
• Optionable: Not Optionable
• Beta: 0.29